4
13
1
↑4
↓13
—1
Evidence suggests Melatonin maydecreaseInfection.
18 studies (18 claims)
Moderate consensus
Typical effective dose 2 (2–2) mgacross 1 dosed study
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| melatonin | Decreases - is a potential and promising agent to help overcome Covid-19 infection | Covid-19 infection | Human | healthy persons and obese and diabetic patients | Not specified | Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19.cited 52× |
| melatonin | Decreases - is a potential adjuvant | Covid-19 infection | Human | Covid-19-infected individuals with diabetes and obesity | Not specified | Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19.cited 52× |
| melatonin | Increases - usefulness as adjuvant drug is probable | COVID-19 infection outcome | Human | — | Not specified | Endocrine and metabolic aspects of COVID-19.cited 4× |
| melatonin | No effect - is likely to afford protection | Ebola viral infection | Human | those at high risk of Ebola viral infection | Not mentioned | Ebola virus: melatonin as a readily available treatment option.cited 40× |
| melatonin | No effect - having direct impacts | the course of infection per se | Human | — | Not mentioned | Ebola virus: melatonin as a readily available treatment option.cited 40× |
| melatonin | Decreases - protect against | H1N1 infection | AnimalMolecular | in vitro and in vivo conditions | — | Melatonin alleviates lung injury in H1N1-infected mice by mast cell inactivation and cytokine storm suppression. |
| melatonin | Decreases - anti-infection | infection | Human | — | Not specified | Effects of propolis and melatonin on oxidative stress, inflammation, and clinical status in patients with primary sepsis: Study protocol and review on previous studies.cited 23× |
| Melatonin | Increases - improved | in vitro fertilization and offspring survival after bacterial infection | AnimalMolecular | — | — | Melatonin improves uterine-conceptus interaction via regulation of SIRT1 during early pregnancy. |
| melatonin | Increases - slightly increased | levels of infection | Molecular | two different cell lines | — | Screening of melatonin, α-tocopherol, folic acid, acetyl-L-carnitine and resveratrol for anti-dengue 2 virus activity. |
| melatonin | Increases - highlight the impact as an adjuvant and a potential alternative for the better management | management of SARS-CoV-2 infection | Human | high-risk populations | — | Melatonin as a complementary and prophylactic agent against COVID-19 in high-risk populations: A narrative review of recent findings from clinical and preclinical studies.cited 2× |
| melatonin | Decreases - antioxidant properties are linked to reduced predisposition to infection and weight gain | predisposition to infection and weight gain | Human | patients with obesity | Not specified | The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review.cited 20× |
| melatonin | No effect - lack of experimental and clinical data on the use | SARS-CoV-2 infection | Human | — | Not specified (injectable formulation for intravenous perfusion). | Clinical trial to test the efficacy of melatonin in COVID-19.cited 54× |
| melatonin | Decreases - reduced | severity of infection | Human | seriously infected COVID-19 patients | Not specified | Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection.cited 29× |
| melatonin | Decreases - can reduce | severity of the infection | Human | — | — | Potential Therapeutic Approach of Melatonin against Omicron and Some Other Variants of SARS-CoV-2.cited 9× |
| Melatonin | Decreases - may be particularly effective at reducing | the signs and symptoms of SARS-CoV-2 infection | Human | — | — | Possible Application of Melatonin in Long COVID.cited 19× |
| melatonin | No effect - suggested as a safe and effective therapeutic option | treatment of SARS‑CoV‑2 infection | Human | — | Not specified. | A mid‑pandemic night's dream: Melatonin, from harbinger of anti‑inflammation to mitochondrial savior in acute and long COVID‑19 (Review).cited 5× |
| melatonin | Decreases - inhibits the entrance of the virus into the cell | viral infection | Human | — | Not specified | Mechanisms and clinical evidence to support melatonin's use in severe COVID-19 patients to lower mortality.cited 16× |
| melatonin receptor blocking | Decreases - block the action of melatonin | malarial infection | Human | man | Not mentioned | Malaria, anti malarial drugs and the role of melatonin.cited 4× |
| melatonin (Circadin®, Exeltis Healthcare, Spain): 2 mg of melatonin orally before bedtime for 12 weeks | Decreases - evaluate the efficacy | prevention of asymptomatic SARS-CoV-2 infection | Human | healthcare workers at high risk of SARS-CoV-2 exposure | 2 mg orally before bedtime. | A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.cited 29× |
| melatonin (Circadin®, Exeltis Healthcare, Spain): 2 mg of melatonin orally before bedtime for 12 weeks | Decreases - evaluate the efficacy | prevention of symptomatic SARS-CoV-2 infection | Human | healthcare workers at high risk of SARS-CoV-2 exposure | 2 mg orally before bedtime. | A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.cited 29× |